Mustang Bio, Inc. General form of registration statement for all companies including face-amount certificate companies

Accounts Payable and Accrued Expenses

9 Months Ended

12 Months Ended

Sep. 30, 2024

Dec. 31, 2023

Note 7 - Accounts Payable and Accrued Expenses

At September 30, 2024, and December 31, 2023, accounts payable and accrued expenses consisted of the following:


	September 30,		December 31,
($ in thousands)	2024		2023
Accounts payable	$	8,759	$	6,322
Accrued research and development		561		4,118
Accrued compensation		984		2,838
Other ⁽¹⁾		1,757		739
Total accounts payable and accrued expenses	$	12,061	$	14,017

⁽¹⁾ Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.

Note 6 - Accounts Payable and Accrued Expenses

At December 31, 2023 and 2022, accounts payable and accrued expenses consisted of the following:


	December 31,
($ in thousands)	2023		2022
Accounts payable	$	6,322	$	6,833
Accrued research and development		4,118		2,782
Accrued compensation		2,838		3,468
Other		739		648
Total accounts payable and accrued expenses	$	14,017	$	13,731